New Studies Validate the Value of Brainomix AI Technology Across US Stroke Networks

    The FDA-cleared Brainomix 360 Stroke platform is powered by state-of-the-art AI algorithms that provide real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients, with the aim of enabling more patients to receive the right treatment, in the right place, at the right time. DrMichalis Papadakis , CEO and Co-Founder of Brainomix, said: "The studies presented this week at SNIS symbolize our ongoing commitment to scientific excellence and...

 

The FDA-cleared Brainomix 360 Stroke platform is powered by state-of-the-art AI algorithms that provide real-time interpretation of brain scans to aid treatment and transfer decisions for stroke patients, with the aim of enabling more patients to receive the right treatment, in the right place, at the right time.

Dr Michalis Papadakis, CEO and Co-Founder of Brainomix, said: "The studies presented this week at SNIS symbolize our ongoing commitment to scientific excellence and reflect the successful partnerships that we have forged with leading academic institutions across the United States to jointly explore the frontiers of stroke AI imaging. Together we are identifying exciting opportunities that may expand the capabilities of physicians to better manage stroke patients across all levels of stroke networks with our technology."

Dr Ansaar Rai, Professor and Chair, Department of Neuroradiology & Neurointerventional Surgery, West Virginia University, said: "The studies presented this week at SNIS highlight the clinical value of the Brainomix 360 Stroke platform, particularly relating to the e-ASPECTS and Triage Stroke algorithms that assess non-contrast CT scans, which are universally available to all stroke centers across the US. The results indicate that these algorithms generate clinically relevant results for frontline stroke physicians that could help them to better manage stroke patients eligible for mechanical thrombectomy across all centers within a network."

Key studies presented at SNIS included:

About Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke and lung fibrosis. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company with offices in the UK, Ireland and the USA, and operations in more than 30 countries. A private company, backed by leading healthtech investors, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Its first product, the Brainomix 360 stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving increased treatment rates and improving functional independence for patients.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts

Jeff Wyrtzen, Chief Marketing & Business Development Officer
[email protected]
M +44 (0)7927 164210
T +44 (0)1865 582730

Media enquiries

Charles Consultants
Sue Charles
[email protected]
M +44 (0)7968 726585

Logo: https://mma.prnewswire.com/media/1989193/3856380/BrainomiLogo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/new-studies-validate-the-value-of-brainomix-ai-technology-across-us-stroke-networks-302206491.html